The results showed that patients with elevated CMTM6 expression may receive better immunotherapeutic response in TCGA-PAAD, GSE57495, and GSE85916 cohorts (Figs. S5A-5C). This evidence concerns the gene CMTM6 and pancreatic adenocarcinoma.